A Study of Imlunestrant (LY3484356) in Female Healthy Participants

NCT05444556 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Imlunestrant
DRUG: Repaglinide
DRUG: Omeprazole
DRUG: Dextromethorphan
DRUG: Quinidine
DRUG: Rosuvastatin
DRUG: Digoxin

Sponsor

Eli Lilly and Company